Docoh
Loading...

GSK Glaxosmithkline

Filed: 27 Nov 20, 7:24am
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of November 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
Issued: 26 November 2020, London UK - LSE Announcement
 
 
Publication of Supplementary Prospectus
 
The following base prospectus dated 26 November 2020 has been approved by the UK Listing Authority and is available for viewing:
 
GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme
 
Copies of the supplementary prospectus have been submitted to the UK Listing Authority's National Storage Mechanism submission portal via the Electronic Submission System.  The base prospectus will shortly be available for inspection at and can be downloaded from:
 
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
 
For further information, please contact:
 
GlaxoSmithKline plc
 
980 Great West Road
 
Brentford
 
Middlesex
 
TW8 9GS
 
United Kingdom
 
 
 
Enquiries:
 
UK Media enquiries:
 
David Mawdsley
Simon Steel
 
(020) 8047 5564
(020) 8047 3763
 
 
European Analyst/Investor enquiries:
 
James Dodwell
Danielle Smith
 
(020) 8047 2406
(020) 8047 0932
 
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY PROSPECTUS
 
Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base prospectus whether or not you are part of the intended addressees of the information contained therein.
 
Your right to access this service is conditional upon complying with the above
 
 
 
 
 
GlaxoSmithKline plc
Registered in England & Wales:
No. 3888792
 
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: November 26, 2020 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc